Dynavax Technologies

Dynavax Technologies is a commercial-stage biopharmaceutical company focused on developing and commercializing novel vaccines to combat infectious diseases. The company utilizes proven and innovative adjuvant technology, such as its CpG 1018® adjuvant, to enhance the effectiveness of vaccines, including its HEPLISAV-B® product. With a commitment to making a global impact on public health, Dynavax actively engages in clinical trials and values driven team collaborations to advance its pipeline of vaccine solutions.